The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-review
Tóm tắt
Từ khóa
Tài liệu tham khảo
M. H. Fisher, H. Mrozik. Chemistry. In W. C. Campbell (ed.), Ivermectin and abamectin: Springer, New York, 1989 pp. 1–23.
J.W. Steel. Pharmacokinetics and metabolism of avermectins in livestock. Vet. Parasitol 48:45–77 (1993).
M. Winne, A. P. Plaisier, E. S. Alley et al. Can ivermectin mass treatments eliminate onchocerciasis in Africa? Bull. WHO 80:384–390 (2002).
D. H. Molyneux, and N. Zagaria. Lymphatic filariasis elimination: progress in global programme development. Ann. Trop. Med. Parasitol 96:15–40 (2002).
A. L. Dourmishev, L. A. Dourmishev, and R. A. Schwartz. Ivermectin: pharmacology and application in dermatology. Int. J. Dermatol 44:981–988 (2005).
D. R. Krishna, and U. Klotz. Determination of ivermectin in human plasma by high-performance liquid chromatography. Arzneimittelforschung 43:609–611 (1993).
Q. C. Long, B. Ren, S. X. Li, and G. X. Zeng. Human pharmacokinetics of orally taken ivermectin. Chin. J. Clin. Pharmacol 17:203–206 (2001).
D. W. Fink, and A. G. Porras. Pharmacokinetics of ivermectin in animals and humans. In W. C. Campbell (ed.), Ivermectin and abamectin: Springer, New York, 1989, pp. 113–130.
G. Edwards, A. Dingsdale, N. Helsby, M. L. Orme, and A. Breckenridge. The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. Eur. J. Clin. Pharmacol 35:681–684 (1988).
O. Z. Baraka, B. M. Mahmoud, C. K. Marschke, T. G. Geary, A. Homeida, and J. F. Williams. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur. J. Clin. Pharmacol 50:407–410 (1996).
J. E. Ogbuokiri, B. C. Ozumba, O. P. Okonkwo. Ivermectin levels in human breast milkEur. J. Clin. Pharmacol 46:389–390 (1993).
S. R. Vanapalli, Y. Chen, V. L. Ellingrod, et al. Orange juice decreases the oral bioavailability of ivermectin in healthy volunteers. 2003 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. Washington (USA), 2–5 April, 2003.
M. H. Elkassaby. Ivermectin uptake and distribution in the plasma and tissue of sudanese and mexican patients infected with Onchocerca volvulus. Trop. Med. Parasitol 42:79–81 (1991).
P. O. Okonkwo, J. E. Ogbuokiri, E. Ofogebu, and U. Klotz. Protein binding and ivermectin estimations in patients with onchocerciasis. Clin. Pharmacol. The 53:426–430 (1993).
F. L. Njoo, W. M. J. Beek, H. J. Keukens, H. Wilgenburg, J. Oosting, and J. S. Stilma. Ivermectin detection in serum of onchocerciasis patients: relationship to adverse reactions. Am. J. Trop. Med. Hyg 52:94–97 (1995).
F. M. Marty, C. M. Lowry, M. Rodriguez et al. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. CID 41:e5–8 (2005).
S. A. Turner, J. D. MacLean, L. Fleckenstein, and C. Greenaway. Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis. Am. J. Trop. Med. Hyg 73:911–914 (2005).
H. F. Cross, B. M. Bronsvoort, G. Wahl, A. Renz, D. Achu-Kwi, and A. J. Trees. The entry of ivermectin and suramin into Onchocerca ochengi nodules. Ann. Trop. Med. Parasitol 91:393–401 (1997).
N. Haas, U. Lindemann, K. Frank et al. Rapid and preferential sebum secretion of ivermectin: a new factor that may determine drug responsiveness in patients with scabies. Arch. Dermatol 138:1618–1619 (2002).
U. Klotz, J. E. Ogbuokiri, and P. O. Okonkwo. Ivermectin binds avidly to plasma proteins. Eur. J. Clin. Pharmacol 39:607–608 (1990).
Z. Zeng, N. W. Andrew, B. H. Arison, D. Luffer-Atlas, and R. W. Wang. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica 28:313–321 (1998).
A. Hoerauf, S. Mand, O. Adjei, B. Fleischer, and D. Büttner. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet 537:1415–1416 (2001).
K. Awadzi, M. Hero, N. O. Opoku et al. The chemotherapy of onchocerciasis: clinical evaluation of albendazole in patients with onchocerciasis; effects of food and pretreatment with ivermectin on drug response and pharmacokinetics. Ann. Trop. Med. Parasitol 45:203–208 (1994).
K. Awadzi, E. T. Addy, N. O. Opoku, A. Plenge-Böning, and D. W. Büttner. The chemotherapy of onchocerciasis: ivermectin in combination with albendazole. Trop. Med. Parasitol 46:213–220 (1995).
K. Awadzi, G. Edwards, B. O. Duke et al. The coadministration of ivermectin and albendazole: safety, pharmacokinetics and efficacy against Onchocerca volvulus. Ann. Trop. Med. Parasitol 97:165–178 (2003).
K. Awadzi, N. O. Opoku, S. K. Attah et al. The safety and efficacy of amorcazine in African onchocerciasis and the influence of ivermectin on the clinical and parasitological response to treatment. Ann. Trop. Med. Parasitol 91:281–296 (1997).
K. Awadzi, G. Edwards, Opoku et al. The safety, tolerability and pharmacokinetics of levamisole alone, levamisole plus ivermectin, and levamisole plus albendazole, and their efficacy against Onchocerca volvulus. Ann. Trop. Med. Parasitol 98:595–614 (2004).
M. M. Ismail, and R. L. Jayakody. Efficacy of albendazole and its combinations with ivermectin or diethylcarbamazine (DEC) in the treatment of Trichuris trichiura infections in Sri Lanka. Ann. Trop. Med. Parasitol 93:501–504 (1999).
M. M. Homeida, I. S. Bagi, H. W. Ghalib et al. Prolongation of prothrombin time with ivermectin. Lancet 1:1346–1347 (1988).
F. O. Richards, M. B. McNeely, R. T. Bryan et al. Ivermectin and prothrombin time. Lancet 1:1139 (1989).
M. C. Pacqué, B. Muñoz, A. T. White, P. N. Williams, and B. M. Greene. Ivermectin and prothrombin time. Lancet 1:1140 (1989).
J. A. Whitworth, C. R. Hay, A. M. McNicholas, D. Morgan, G. H. Maude, and D. W. Taylor. Coagulation abnormalities and ivermectin. Ann. Trop. Med. Parasitol 86:301–305 (1992).
M. A. Fernández, S. Ballesteros, and J. Aznar. Oral anticoagulants and insecticides. Thromb. Haemost 80:724 (1998).